Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology

• Main Authors: Rivoltini Licia, Ribas Antoni, Pos Zoltan, Petricoin Emanuel F, Palucka A Karolina, Nishikawa Hiroyoshi, Nakamura Kiminori, Mayrand-Chung Shawmarie, Masucci Giuseppe, Matsubara Hisahiro, Malyguine Anatoli, Maio Michele, Lotze Michael T, Liotta Lance, Lehmann Paul V, Kleen Thomas O, Kirkwood John M, Kawakami Yutaka, Kato Kazunori, Kashani-Sabet Mohammed, Kanamoto Akira, Jinushi Masahisa, Jacobson James, Hirohashi Yoshihiko, Imai Kohzoh, Fridman Wolf, Eremin Oleg, Doki Yuichiro, Chaussabel Damien, Akutsu Yasunori, Ambs Stefan, Wigginton Jon M, Lee Peter P, Khleif Samir N, Fox Bernard A, Disis Mary L, Butterfield Lisa H, Wang Ena, Thurin Magdalena, Sato Marimo, Tahara Hideaki, Sato Noriyuki, Shiku Hiroshi, Slingluff Craig L, Streicher Howard, Stroncek David F, Takeuchi Hiroya, Toyota Minoru, Wada Hisashi, Wu Xifeng, Wulfkuhle Julia, Yaguchi Tomonori, Zeskind Benjamin, Zhao Yingdong, Zocca Mai-Britt, Marincola Francesco M
• Format: Article
• Language: English
• Published: BMC 2009-06-01
• Series: Journal of Translational Medicine
• Online Access: http://www.translational-medicine.com/content/7/1/45

<p>Abstract</p> <p>Supported by the Office of International Affairs, National Cancer Institute (NCI), the "<it>US-Japan Workshop on Immunological Biomarkers in Oncology</it>" was held in March 2009. The workshop was related to a task force launched by the International Society for the Biological Therapy of Cancer (iSBTc) and the United States Food and Drug Administration (FDA) to identify strategies for biomarker discovery and validation in the field of biotherapy. The effort will culminate on October 28^th2009 in the <it>"iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer"</it>, which will be held in Washington DC in association with the Annual Meeting. The purposes of the US-Japan workshop were a) to discuss novel approaches to enhance the discovery of predictive and/or prognostic markers in cancer immunotherapy; b) to define the state of the science in biomarker discovery and validation. The participation of Japanese and US scientists provided the opportunity to identify shared or discordant themes across the distinct immune genetic background and the diverse prevalence of disease between the two Nations.</p> <p>Converging concepts were identified: enhanced knowledge of interferon-related pathways was found to be central to the understanding of immune-mediated tissue-specific destruction (TSD) of which tumor rejection is a representative facet. Although the expression of interferon-stimulated genes (ISGs) likely mediates the inflammatory process leading to tumor rejection, it is insufficient by itself and the associated mechanisms need to be identified. It is likely that adaptive immune responses play a broader role in tumor rejection than those strictly related to their antigen-specificity; likely, their primary role is to trigger an acute and tissue-specific inflammatory response at the tumor site that leads to rejection upon recruitment of additional innate and adaptive immune mechanisms.</p> <p>Other candidate systemic and/or tissue-specific biomarkers were recognized that might be added to the list of known entities applicable in immunotherapy trials. The need for a systematic approach to biomarker discovery that takes advantage of powerful high-throughput technologies was recognized; it was clear from the current state of the science that immunotherapy is still in a discovery phase and only a few of the current biomarkers warrant extensive validation. It was, finally, clear that, while current technologies have almost limitless potential, inadequate study design, limited standardization and cross-validation among laboratories and suboptimal comparability of data remain major road blocks. The institution of an interactive consortium for high throughput molecular monitoring of clinical trials with voluntary participation might provide cost-effective solutions.</p>